fgfr-4-in-4

FGFR-IN-4 is a potent inhibitor of FGFR with potential applications in cancer disease studies.

FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.

FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.

FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.

FGFR-IN-15 (compound 18i) acts as a pan-FGFR inhibitor, exhibiting potent inhibitory activity against FGFR1-4.

FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1 2 3 4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1 2 3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.

FGFR4-IN-5, a covalent FGFR4 inhibitor, demonstrates potency and selectivity with an IC50 value of 6.5 nM. Exhibiting significant in vivo anti-tumor activity, it is applicable for research in hepatocellular carcinoma [1].

FGFR-IN-8 is a potent, orally active FGFR inhibitor that inhibits both wild-type and mutant FGFR. FGFR-IN-8 acts on FGFR1 (IC50<0.5 nM), V564F-FGFR2 (IC5016: 189.1 nM), N549H-FGFR2 (IC50<0.5 nM), V555M-FGFR3 (IC50: 22.6 nM), FGFR3 (IC50<0.5 nM) and FGFR 4 (IC50: 7.30 nM), V555M-FGFR3 (IC50: 22.6 nM), FGFR3 (IC50<0.5 nM) and FGFR 4 (IC50: 7.30 nM). FGFR-IN-8 induces apoptosis and exhibits anti-cancer effects.

ODM-203 sodium is an orally available, selective, and efficient FGFR and VEGFR inhibitor, with antitumor activity, inhibiting FGFR3 1 2 and VEGFR3 2 1 4, inducing antitumor immunity, useful in solid tumor research.

FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of FGFR-4, employed in cancer research [1].

FGFR4-IN-1 is a potent FGFR4 inhibitor (IC50: 0.7 nM).